The company didn’t share specific data for the molecule, gefurulimab, but said it hit all endpoints in the Phase III PREVAIL ...

AstraZeneca PLC (NASDAQ:AZN) is one of the Stocks With Huge Catalysts on the Horizon. On July 24, AstraZeneca PLC (NASDAQ:AZN ...

Days of Our Lives army, stand down. Suzanne Rogers isn't going anywhere.

The pharma sees the drug, gefurulimab, as a more convenient, self-administered alternative to the infused medicines it sells ...

Myasthenia gravis, or MG, is "a chronic autoimmune neuromuscular disorder that causes muscle weakness and fatigue," says Hesterlee. It occurs "when a person’s immune system is essentially ...

AstraZeneca's gefurulimab showed clinical benefits and favorable safety in Phase 3 trial for adults with anti-AChR ...

AstraZeneca (NASDAQ:AZN) announced Thursday that gefurulimab, its experimental injectable for generalized myasthenia gravis, ...

AstraZeneca said on Thursday its experimental therapy, gefurulimab, met the primary goal and all secondary endpoints in a ...

AstraZeneca (LSE:AZN) announced promising trial results for gefurulimab, a potential new treatment for generalized myasthenia ...

Myasthenia Gravis is further subdivided into the following types based on their signs and symptoms. Generalised Myasthenia Gravis- This occurs when weakness occurs in multiple groups of muscles.

Gefurulimab is a dual-binding nanobody designed to bind to the C5 protein in the terminal complement cascade and prevent the overactivation of the body’s immune system.

If you happen to be on medicine for myasthenia gravis, don't forget it. Any type of light aerobic exercise or anything that you're used to doing, feel free to do.